The Trial of Elizabeth Holmes: Theranos on Trial

Reading Time: 6 minutes ·

In 2014, Elizabeth Holmes was the most celebrated young founder in Silicon Valley. Her company, Theranos, claimed to have invented a device that could run hundreds of blood tests from a single finger prick — a breakthrough that would, she said, transform medicine. She was 30 years old, worth an estimated 4.5 billion dollars on paper, and on the cover of business magazines. She wore a black turtleneck, spoke in a deep voice, and quoted Steve Jobs. Investors, politicians, and the press treated her as a genius.

By 2018, the company was worth nothing, Holmes was facing criminal charges, and the question before a court in California was whether she had been a visionary who believed too deeply in her own idea, or a fraudster who had knowingly sold a product that did not work. Her trial, which ran from August 2021 to January 2022, became the defining courtroom drama of the Silicon Valley era — a case about ambition, deception, and the difference between a bold promise and a lie.

The rise of Theranos

Holmes founded Theranos in 2003, at the age of 19, after dropping out of Stanford University. The idea was simple and, if it worked, revolutionary: a small device, later called the Edison, that could perform dozens of laboratory tests on a few drops of blood taken from a fingertip, quickly and cheaply. It would bring the laboratory to the pharmacy counter, and it would make blood testing painless.

For more than a decade, the company operated in secrecy. Holmes said the technology was proprietary and refused to publish peer-reviewed research or allow independent scientists to examine it. Instead, she raised money on the strength of her own reputation and the endorsements of powerful figures. Theranos attracted investment from some of the richest people in America, signed a partnership with the pharmacy chain Walgreens to offer its tests in stores, and assembled a board that included former secretaries of state, generals, and a former secretary of defence. At its peak in 2014, the company was valued at about 9 billion dollars, and Holmes’s own stake was estimated at 4.5 billion, making her, on paper, the youngest self-made female billionaire in the world.

The Wall Street Journal investigation

The story began to unravel in October 2015, when the Wall Street Journal published an investigation by reporter John Carreyrou. Drawing on interviews with former employees, Carreyrou reported that the Edison device did not work as claimed: that it could perform only a small number of tests, that most of the tests Theranos offered were run on ordinary commercial machines bought from other companies, and that the results were often unreliable. Former employees described a culture of secrecy and intimidation, and said that staff who raised concerns were pushed out.

Holmes and Theranos denied the reports and threatened legal action. But the evidence mounted. In 2016, the federal agency that regulates laboratories found serious problems with Theranos’s testing facility, and banned Holmes from owning or operating a laboratory for two years. Walgreens ended the partnership. Investors sued. By 2018, the company had collapsed, and its remaining assets were sold off. Holmes’s fortune, which had existed only on paper, vanished.

In March 2018, the Securities and Exchange Commission charged Holmes and the company’s president and chief operating officer, Ramesh “Sunny” Balwani, with fraud. Holmes settled the civil case, paying a 500,000-dollar penalty and agreeing not to serve as an officer or director of a public company for ten years. Three months later, in June 2018, a federal grand jury indicted both of them on criminal charges: eleven counts of wire fraud and conspiracy to commit wire fraud, relating to claims made to investors and to patients.

The trial

Holmes’s trial began on 31 August 2021 in federal court in San Jose, California, after delays caused by the COVID-19 pandemic and by Holmes’s pregnancy. It lasted four months. The prosecution called 29 witnesses, including former Theranos employees, investors, and patients. Their case was straightforward: that Holmes had knowingly misled investors about the capabilities of the Edison device, about the company’s finances, and about its relationships with pharmaceutical companies and the military. They showed the jury internal documents in which Holmes had claimed partnerships that did not exist, and they played recordings of her making claims about the technology that the company’s own scientists knew were false.

One of the most damaging witnesses was Adam Rosendorff, Theranos’s former laboratory director, who testified that he had repeatedly warned Holmes that the tests were unreliable, and that she had pressed ahead anyway. Another was a former employee who described how the company had rigged demonstrations for visitors, running tests on commercial machines while pretending the Edison was doing the work.

Holmes took the stand in her own defence, testifying for seven days — an unusual and risky move for a defendant in a fraud trial. She admitted that mistakes had been made, but said she had believed in the technology and had never intended to deceive anyone. She described herself as a young founder who had trusted her scientists and her team. She also testified, for the first time in public, that Balwani had been controlling and abusive towards her during their relationship, and that his behaviour had affected her judgment. Balwani, who was tried separately, denied the claims.

The defence’s argument was that Holmes was a sincere believer in her own company — an ambitious founder who had made mistakes, but not a criminal. The prosecution’s answer was that belief is not a defence when the evidence shows that you knew the truth and said the opposite.

The verdict

On 3 January 2022, after seven days of deliberation, the jury returned its verdict. Holmes was found guilty on four counts: one count of conspiracy to defraud investors, and three counts of wire fraud against investors. She was acquitted on four counts relating to patients, and the jury could not reach a verdict on three further counts, which were later dismissed. The split verdict was, in effect, a finding that Holmes had defrauded the rich people who had invested in Theranos, but that the prosecution had not proved beyond reasonable doubt that she had defrauded the patients who had taken its tests.

On 18 November 2022, Judge Edward Davila sentenced Holmes to 11 years and three months in federal prison, and ordered her to pay 452 million dollars in restitution to investors. Balwani was tried separately and convicted in July 2022 on all twelve counts against him; he was sentenced in December 2022 to almost 13 years in prison. Holmes reported to the Federal Prison Camp in Bryan, Texas, on 30 May 2023. The Bureau of Prisons later projected her release for December 2032, taking account of good conduct time, and in March 2026 a judge reduced her sentence by twelve months under revised federal sentencing guidelines, bringing her projected full release to early 2030. She has appealed her conviction.

What the trial meant

The trial of Elizabeth Holmes became a symbol of a particular moment in American business culture. Theranos was not an ordinary fraud: it was a company that had been celebrated by the press, backed by some of the most powerful people in the country, and valued at billions of dollars, all on the basis of a technology that did not work. The trial forced a reckoning with how that had happened — with the willingness of investors to hand over money without demanding proof, with the media’s appetite for a story about a young female genius, and with the culture of Silicon Valley, where bold claims are rewarded and scepticism is treated as a failure of imagination.

The trial also raised a question that has no clean answer: where does optimism end and fraud begin? Every founder exaggerates. Every startup promises more than it can yet deliver. The jury’s verdict drew a line, but it was a narrow one. Holmes was convicted of lying to investors about specific facts — about partnerships, about the military’s use of the device, about the company’s finances — not for being ambitious, and not for believing in her own idea. The distinction matters, and it is the reason the trial was watched so closely by founders and investors across the technology industry.

For the patients, the outcome was less satisfying. The jury acquitted Holmes on the counts relating to patients, even though the evidence showed that some patients had received wrong results. The acquittal did not mean the tests were reliable; it meant the prosecution had not proved, to the criminal standard, that Holmes had intended to defraud those particular patients. It was a reminder that a fraud trial is not a judgment on a whole company, but a test of specific charges against specific people.

What is documented — and what is not

Documented: Elizabeth Holmes founded Theranos in 2003 and raised hundreds of millions of dollars on claims about a blood-testing device, the Edison, that the company’s own scientists knew did not work as advertised. A Wall Street Journal investigation in October 2015 exposed the problems. Holmes was indicted in June 2018 on eleven counts of wire fraud and conspiracy. At her trial in San Jose, which ran from August 2021 to January 2022, she was convicted on four counts relating to investors, acquitted on four counts relating to patients, and the jury deadlocked on three. She was sentenced on 18 November 2022 to 11 years and three months in prison and ordered to pay 452 million dollars in restitution. She reported to the Federal Prison Camp in Bryan, Texas, on 30 May 2023. In March 2026 a judge reduced her sentence by twelve months.

Unverified or unproven: That Holmes set out from the beginning to commit fraud — the prosecution’s case was that she knowingly misled investors over a period of years, but when she first began to believe the technology would work, and when that belief became deception, is a matter the trial did not settle with precision. Her claims about Balwani’s behaviour towards her were her own testimony and were denied by him; they were not tested by a separate finding. Any claim that investors were warned in writing about the risks and chose to ignore them is a matter for the civil cases, not a finding of the criminal trial.

Sources

Leave a Comment